BIOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), BioPlus Acquisition's share price is $10.795. BioPlus Acquisition's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.06. Hence, BioPlus Acquisition's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for BioPlus Acquisition's Price-to-Free-Cash-Flow or its related term are showing as below:
BioPlus Acquisition's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.04. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.06.
The historical data trend for BioPlus Acquisition's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPlus Acquisition Annual Data | |||||
Trend | Dec21 | Dec22 | |||
Price-to-Free-Cash-Flow | - | - |
BioPlus Acquisition Quarterly Data | ||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Shell Companies subindustry, BioPlus Acquisition's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BioPlus Acquisition's Price-to-Free-Cash-Flow falls into.
BioPlus Acquisition's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 10.795 | / | -0.061 | |
= | N/A |
BioPlus Acquisition's Share Price of today is $10.795.
BioPlus Acquisition's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
BioPlus Acquisition (NAS:BIOS) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of BioPlus Acquisition's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven C. Fletcher | 10 percent owner | C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807 |
Explorer Parent Llc | 10 percent owner | 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012 |
Founder Holdings Llc | 10 percent owner | 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012 |
Alex Serge Vieux | 10 percent owner | C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749 |
Bioplus Sponsor Llc | 10 percent owner | 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
Louis G Lange | director | 3172 PORTER DRIVE, PALO ALTO CA 94034 |
Ross Haghighat | director, officer: CEO and CFO | C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710 |
Ronald W Eastman | director | 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301 |
Shawn Cross | director | 1825 K STREET SUITE 510, WASHINGTON DC 20006 |
Jonathan Rigby | director, officer: Chief Business Officer | ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545 |
Glen Giovannetti | director | UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000 |
From GuruFocus
By Marketwired • 08-16-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 10-04-2023
By Marketwired • 10-04-2023
By sperokesalga sperokesalga • 06-13-2023
By GuruFocusNews GuruFocusNews • 12-06-2021
By Marketwired • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.